



Aussie medicinal cannabis company, Greenfield MC Global, launches crowd funding campaign offering investment opportunities for under \$250

The CSF is open now and will close on 12 December 2019, via capitallabs.com/greenfieldmc

Greenfield MC Global, an Australian-owned medicinal cannabis company, has launched an equity crowd-sourced funding (CSF) campaign offering an opportunity for small Australian investors – and first-time investors – to become shareholders in and part-owners of the rapidly growing company. With a minimum investment amount set at just \$242, Greenfield MC Global's CSF has been positioned to make it accessible to people who may not ordinarily consider investing. "In the weeks before launching our CSF, we achieved phenomenal success with our Series B investment round, securing \$1.75 million from a wide range of experienced investors, including medical experts, lawyers, high profile business leaders and even celebrities," explained Nicholas Hanna, CEO of Greenfield MC Global. "With this latest crowd-sourced funding campaign we wanted to open up the opportunity to invest in Greenfield MC Global to the hundreds of smaller investors who reached out to us during our last funding round." As the number of patients being approved to access medicinal cannabis in Australia continues to soar – with the latest figures showing a 985% increase in approvals from October 2018 to October 2019[1] – Greenfield MC Global will maintain its primary focus on the cultivation, manufacture and distribution of pharmaceutical-grade medicinal cannabis, while also commencing research projects in both New Zealand and the Philippines, and continuing to import high-quality medicinal cannabis for distribution within Australia, from a range of trusted international sources. "We are passionate about the potential of medicinal cannabis to positively impact patients' lives and we want to ensure that every Australian who needs it, can get it," said Greenfield MC Global's Chair and President, Arjun Chhabra. "If the worldwide opioid epidemic has shown us anything, it's that the status quo approach to patient healthcare, treatment and management needs to change, and we want to be a part of that change. We're excited to invite Australians who also believe in the power of medicinal cannabis to join us on our mission to revolutionise healthcare in this country." Greenfield MC Global also welcomed the new Parliamentary Inquiry into the accessibility and regulation of medicinal cannabis in Australia announced last week, with Chief Operations Officer Katy Williams Day adding, "We look forward to the findings of the Senate's Community Affairs Committee from the Parliamentary Inquiry next February with great anticipation. Improving the accessibility and affordability of medicinal cannabis for Australians is a key priority for Greenfield MC Global and we hope that this Inquiry accurately identifies the existing barriers and outlines ways to effectively reform the system." Greenfield MC Global's CSF is offered via Capital Labs, the equity CSF platform of The iQ Group Global, and one of the first equity CSF platforms to be approved by ASIC. The CSF is open now and will close on 12 December 2019 capitallabs.com/greenfieldmc

Medicinal Cannabis – Key Facts

The global medicinal cannabis industry is predicted to be worth US\$150bn by 2025[2] The medicinal cannabis market in APAC is expected to tip USD\$5.8bn by 2024[3]. More than 3,500 approvals for medicinal cannabis were issued in Australia via the Special Access Scheme in October 2019, an increase of 985% in 12 months[4] Up to 20,000 new patients are expected to enter the medicinal cannabis market in Australia over the next 12 months[5] A new Federal Parliamentary Inquiry into the accessibility and regulation of medicinal cannabis in Australia was announced on 14 November 2019, with the report due in February 2020 Legislation was amended to allow research into and cultivation of cannabis for medicinal use in Australia in 2016 Medicinal cannabis is currently approved for use in 42 different health conditions in Australia, including some forms of epilepsy, some cancers and side-effects of cancer, chronic pain, inflammatory conditions, neurological conditions and more. – ENDS – Distributed by Uproar Marketing on behalf of Greenfield MC Global Media contact: Rachel McDougall | rachel@uproarmarketing.com.au | 0401 694 301

NOTES FOR EDITORS

Images and Video Resources

A collection of high-resolution images, including photographs of Greenfield MC Global CEO Nicholas Hanna visiting Canadian cannabis producer EPHS Holdings' cultivation site 43 second promo video – featuring Dr Ben Barresi and Arjun Chhabra About Greenfield MC Global Greenfield MC Global is a licenced medicinal cannabis importer and distributor in Australia, with expanding operations in cultivation, research and distribution in the Asia-Pacific region. Independent and privately owned, Greenfield MC Global focuses on medicine, science and results. Formed in 2018, Greenfield MC has a vision to be Asia-Pacific's leading wholesaler and patient-retailer of medicinal cannabis products. Headquartered in Sydney, Australia, Greenfield MC Global is also represented across Melbourne and Brisbane in Australia, as well as New Zealand, South Korea and the Philippines. For further information visit: www.greenfieldmc.com.au About Capital Labs Capital Labs is an equity crowd-funding platform dedicated to launching innovations with impact. Partnering only with companies launching technology and innovations that have a positive influence on the world, Capital Labs enables early stage companies and start-ups to raise capital from investors in exchange for shares in their business. Capital Labs is powered by The iQ Group Global, a group of companies that find, fund and develop bioscience discoveries to create life-changing medical innovations. For further information visit: <https://capitallabs.com> and www.theiqgroupglobal.com. [1] Fresh Leaf Analytics Oct 2019 [2] Grandview Research 2018 [3] Prohibition Partners, The Asian Cannabis Report, May 2019 [4] Fresh Leaf Analytics Oct 2019 [5] Fresh Leaf Analytics: Patient, Product and Pricing Analysis Q1 2019

Contacts

Rachel McDougall

0401694301

mailto: